Cargando…

Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System

Introduction: The analysis of pharmacovigilance databases is crucial for the safety profiling of new and repurposed drugs, especially in the COVID-19 era. Traditional pharmacovigilance analyses–based on disproportionality approaches–cannot usually account for the complexity of spontaneous reports of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fusaroli, Michele, Raschi, Emanuel, Gatti, Milo, De Ponti, Fabrizio, Poluzzi, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694570/ https://www.ncbi.nlm.nih.gov/pubmed/34955821 http://dx.doi.org/10.3389/fphar.2021.740707

Ejemplares similares

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
por: Raschi, Emanuel, et al.
Publicado: (2020)

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2022)

Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal
por: Raschi, Emanuel, et al.
Publicado: (2022)

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
por: Poluzzi, Elisabetta, et al.
Publicado: (2013)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
por: Gatti, Milo, et al.
Publicado: (2020)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
por: Gatti, Milo, et al.
Publicado: (2021)

Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2023)

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
por: Gatti, Milo, et al.
Publicado: (2021)

Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study
por: Gatti, Milo, et al.
Publicado: (2019)

Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People
por: Lunghi, Carlotta, et al.
Publicado: (2022)

Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry
por: Aiello, Valeria, et al.
Publicado: (2021)

Stroke, Migraine and Triptans: From Bedside to Bench
por: Raschi, Emanuel, et al.
Publicado: (2016)

Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
por: Sisi, Monia, et al.
Publicado: (2022)

PSAT122 The Changing Face of Drug-Induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Dalmazi, Guido D, et al.
Publicado: (2022)

Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors
por: Raschi, Emanuel, et al.
Publicado: (2019)

Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
por: Gatti, Milo, et al.
Publicado: (2020)

Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Poluzzi, Elisabetta, et al.
Publicado: (2015)

Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis
por: Filippini, Daria Maria, et al.
Publicado: (2021)

Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe
por: Raschi, Emanuel, et al.
Publicado: (2013)

Recurrence of pericarditis after influenza vaccination: a case report and review of the literature
por: Mei, Riccardo, et al.
Publicado: (2018)

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
por: Raschi, Emanuel, et al.
Publicado: (2018)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
por: Poluzzi, Elisabetta, et al.
Publicado: (2014)

Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study
por: Fusaroli, Michele, et al.
Publicado: (2023)

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
por: Gatti, Milo, et al.
Publicado: (2020)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey
por: Girardi, Anna, et al.
Publicado: (2014)

Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
por: Girardi, Anna, et al.
Publicado: (2015)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i4c7af2r2pp6v1l4hfbooivkqa